CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

Non-Sponsored Content

By: News Feed | Last updated: 5th October 2018 | In: Haematology, ImmunoOncology, Immunotherapy, Medical News Asia, Oncology

Article Keywords

axicabtagene ciloleucel, B-cell lymphoma, CAR-CD19-T, CAR-T, CD19, Daiichi Sankyo, DLBCL, Gilead Sciences, HGBL, Kite Pharma, KTE-C19, lymphoma, NHL, non-Hodgkin, PMBCL, TFL, Yescarta

TOKYO and BASKING RIDGE, N.J., October 3, 2018 /PRNewswire/ — The Japan혻Ministry of Health, Labour and Welfare (MHLW) granted the혻Orphan Drug designation to혻axicabtagene ciloleucel혻(KTE-C19, Daiichi Sankyo)혻for the treatment of혻diffuse large B-cell lymphoma (DLBCL),혻primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBL), and transformed follicular lymphoma (TFL), which are all aggressive forms of혻non-Hodgkin lymphoma (NHL).

“Receiving Orphan Drug designation is an important step in expediting the development of axicabtagene ciloleucel in Japan and underscores the unmet needs of patients with these aggressive forms of relapsed or refractory B-cell lymphomas”

Kouichi Akahane, Head of Oncology Function, R&D Division, Daiichi Sankyo

Axicabtagene ciloleucel혻is a chimeric antigen receptor T-cell (CAR-T) therapy directed against CD19.혻The drug enables the혻patient’s innate immune system to eradicate certain types of B-cell lymphoma cells. Axicabtagene ciloleucel혻was previously approved in the United States (US) and Europe based on the results of the Phase 1/2 ZUMA-1 study. A similar design study to the ZUMA-1 is currently being planned in Japan.

Daiichi Sankyo obtained the exclusive development, manufacturing and commercialisation rights in Japan for axicabtagene ciloleucel혻from Kite Pharma, a Gilead company. In the US and Europe, the CAR-T therapy is marketed as Yescarta짰.

The Orphan Drug designation system by the Japan MHLW is designed to promote research and support the development of therapies for severe and difficult-to-treat diseases affecting less than 50,000 Japanese patients, and for which a major unmet medical need.

References

Daiichi Sankyo. (2018, October 03) Japan MHLW Grants Orphan Drug Designation to Axicabtagene Ciloleucel for Treatment of Certain Types of B-Cell Lymphoma [Press Release]. Retrieved from https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006911.html

Newsletter Sign-Up

Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.

Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

TIGR짰Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

26th April 2019

Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

16th January 2019

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

Non-Sponsored Content